



01-06-04
image.

CASE 4-100-8303C

1714
1646

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV335545355US

Express Mail Label Number

January 5, 2004

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1714

SCHULER ET AL.

APPLICATION NO: 10/092,639

FILED: MARCH 7, 2002

FOR: USE OF RAPAMYCIN DERIVATIVES IN VASCULOPATHIES AND
XENOTRANSPLANTATION

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed October 4, 2002. Since Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7909


Thomas R. Savitsky
Attorney for Applicants
Reg. No. 31,661

Date: *January 2, 2004*

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.
4-100-8303C
APPLICATION NO.
10/092,639
APPLICANT
SCHULER ET AL.
FILING DATE
MARCH 7, 2002

Group
1714

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|----------|-------------|
| | CA | | | | | | |
| | CB | | | | | | |
| | CC | | | | | | |
| | CD | | | | | | |
| | CE | | | | | | |
| | CF | | | | | | |
| | CG | | | | | | |
| | CH | | | | | | |
| | CI | | | | | | |
| | CJ | | | | | | |
| | CK | | | | | | |
| | CL | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | OFFICE | CLASS | SUBCLASS | TRANSLATION | |
|--|----|-----------------|------|--------|-------|----------|--------------------------|--------------------------|
| | | | | | | | YES | NO |
| | CM | | | | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | CN | | | | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | CO | | | | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | CP | | | | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | CQ | | | | | | <input type="checkbox"/> | <input type="checkbox"/> |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

| | |
|----|---|
| CR | Gregory et al., "Use of Antiproliferative Agents for the Treatment of Occlusive Vascular Disease", FASEB Journal Abstracts Part I, Anaheim, California, April 5-9, p. A940, No. 21 (1992). |
| CS | Gregory et al., "Rapamycin Inhibits Arterial Intimal Thickening Caused by Both Alloimmune and Mechanical Injury", Transplantation, Vol. 55, No. 6, pp. 1409-1418 (1993). |
| CT | Marx et al., "Rapamycin Inhibits Phosphorylation of Retinoblastoma Protein and Blocks Vascular Smooth Muscle Cell Proliferation", Circulation, Vol. 90, No. 4, Part 2, p. I-306, No. 1646 (1994). |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.